Delving into the Latest Updates on 426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication-

Originator Organization

National Institute of Allergy & Infectious Diseases

Active Organization

HIV Vaccine Trials NetworkNational Institute of Allergy & Infectious Diseases

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This is a partially randomized, open-label phase 1 study to evaluate the safety and immunogenicity of a priming regimen of 426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum followed by boosts with HxB2.WT.Core-C4b adjuvanted with 3M-052 AF + Alum.
The primary hypothesis is that the boosting with HxB2.WT.Core-C4b adjuvanted with 3M-052 AF + Alum will further mature broadly neutralizing antibody (bnAb)-precursor B-cell lineages elicited by 426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum.
426c.Mod.Core-C4b adjuvanted with 3M-052 AF + Alum has been tested in HVTN 301 previously, whereas the HxB2.WT.Core-C4b will be first-in-human (FIH).

Start Date17 Mar 2025

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with 426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases)

Login to view more data

100 Translational Medicine associated with 426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases)

Login to view more data

100 Patents (Medical) associated with 426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases)

Login to view more data

100 Deals associated with 426c.Mod.Core-C4b vaccine(National Institute of Allergy and Infectious Diseases)

Login to view more data